Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Repurposing of Approved Drugs with Potential to Block SARS-CoV-2 Surface Glycoprotein Interaction with Host Receptor

Version 1 : Received: 19 April 2020 / Approved: 20 April 2020 / Online: 20 April 2020 (16:01:29 CEST)
Version 2 : Received: 30 July 2020 / Approved: 2 August 2020 / Online: 2 August 2020 (09:23:18 CEST)

How to cite: Sajib, A. Repurposing of Approved Drugs with Potential to Block SARS-CoV-2 Surface Glycoprotein Interaction with Host Receptor. Preprints 2020, 2020040369 (doi: 10.20944/preprints202004.0369.v1). Sajib, A. Repurposing of Approved Drugs with Potential to Block SARS-CoV-2 Surface Glycoprotein Interaction with Host Receptor. Preprints 2020, 2020040369 (doi: 10.20944/preprints202004.0369.v1).

Abstract

Background: Respiratory transmission is the primary route of SARS-CoV-2 infection. Angiotensin I converting enzyme 2 (ACE2) is the known receptor of SARS-CoV-2 spike glycoprotein for entry into human cells. A recent study reported absent to low ACE2 promoter activity in a variety of human lung epithelial cell samples. Three bioprojects (PRJEB4337, PRJNA270632 and PRJNA280600) invariably found abundant expression of ACE in human lungs compared to very low expression of ACE2. Methods: In silico tools were applied to assess potential interaction of SARS-CoV-2 surface spike protein with human ACE as well as predict the drugs that may block SARS-CoV-2 interaction with host receptor. Results: Although it is not obvious from the primary sequence alignment of ACE2 and its homolog ACE (also known as ACE1), comparison of X-ray crystallographic structures show striking similarity in the regions of these proteins which is known (for ACE2) to interact with the receptor binding domain (RBD) of SARS-CoV-2 spike protein. Critical amino acids that mediate interaction with the viral spike protein in ACE2 are organized in the same order in ACE. In silico analyses predicts comparable interaction of SARS-CoV-2 spike protein with ACE2 and ACE. In addition, this study predicts and selects already approved drugs from a list of 1263, which may interfere with the binding of SARS-CoV-2 spike glycoprotein to ACE2 and/or ACE.

Subject Areas

COVID-19; SARS-CoV-2; Spike protein; ACE; ACE2

Comments (1)

Comment 1
Received: 22 April 2020
The commenter has declared there is no conflict of interests.
Comment: No MD simulation done. So many comprehensive work have been done already on it. So, just docking is meaningless, nothing add to science. I following papers provide more insight. https://www.nature.com/articles/s41421-020-0153-3 https://www.researchgate.net/publication/339388181_Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface https://chemrxiv.org/articles/Identification_of_SARS-CoV-2_Cell_Entry_Inhibitors_by_Drug_Repurposing_Using_in_Silico_Structure-Based_Virtual_Screening_Approach/12005988/2?file=22282821 https://www.researchgate.net/publication/340122235_Virtual_Screening_of_Inhibitors_Against_Spike_Glycoprotein_of_SARS-CoV-2_A_Drug_Repurposing_Approach https://arxiv.org/pdf/2003.14333.pdf https://www.sciencedirect.com/science/article/pii/S1359644620301458 https://aac.asm.org/content/58/8/4885 https://www.tebu-bio.com/blog/2020/03/27/new-sars-cov-ace2-inhibitor-assays-and-small-molecules-for-drug-discovery/ https://s3-eu-west-1.amazonaws.com/itempdf74155353254prod/11871402/Repurposing_Therapeutics_for_COVID-19__Supercomputer-Based_Docking_to_the_SARS-CoV-2_Viral_Spike_Protein_and_Viral_Spike_v4.pdf https://www.researchgate.net/publication/339388181_Repurposing_Therapeutics_for_the_Wuhan_Coronavirus_nCov-2019_Supercomputer-Based_Docking_to_the_Viral_S_Protein_and_Human_ACE2_Interface
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.